Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 3/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL808997 | 1.00 | CYP2C19 (0.44) | CYP2C19CYP2C9ALDH1A1CYP1A2HPGD | |
| SCHEMBL808818 | 0.87 | KCNJ11 (0.40) | CYP2C19CYP2C9ALDH1A1CYP1A2LMNA | |
| SCHEMBL808817 | 0.87 | KCNJ11 (0.40) | CYP2C19CYP2C9ALDH1A1CYP1A2LMNA | |
| SCHEMBL808895 | 0.85 | KIF11 (0.39) | CYP2C19CYP2C9ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL808894 | 0.85 | KIF11 (0.39) | CYP2C19CYP2C9ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL809008 | 0.84 | RAB9A (0.46) | ALDH1A1CYP1A2HSD17B10HIF1AKDM4E | |
| SCHEMBL809007 | 0.84 | RAB9A (0.46) | ALDH1A1CYP1A2HSD17B10HIF1AKDM4E | |
| SCHEMBL808769 | 0.81 | KMT2A (0.41) | KIF11MEN1POLBKMT2A | |
| SCHEMBL808770 | 0.81 | KMT2A (0.41) | KIF11MEN1POLBKMT2A | |
| SCHEMBL809175 | 0.79 | ALDH1A1 (0.47) | CYP2C19CYP2C9ALDH1A1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1593674-B1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7683215-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-23 | — | — | US | disclosed |
| US-7671213-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20080076941-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ITAGAKI MAKOTO | 2008-03-27 | — | — | US | disclosed |
| US-20080076931-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ITAGAKI MAKOTO | 2008-03-27 | — | — | US | disclosed |
| US-7288674-B2 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-05-03 | — | — | US | disclosed |
| EP-1698616-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1593674-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149077-A1 | Optically active bisoxazoline compounds, process for production of the same and use thereof | ACSL3, ADSL, SQLE | CYP2C19 103/4885CYP2C9 22/4885ALDH1A1 897/4885 |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | CCNL2, ARL1, ACSL3 | CYP2C19 1911/4885CYP2C9 1613/4885ALDH1A1 1303/4885 |
| US-20080076941-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ACSL3, ADSL, SQLE | CYP2C19 103/4885CYP2C9 22/4885ALDH1A1 897/4885 |
| US-20080076931-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF | ACSL3, ADSL, SQLE | CYP2C19 103/4885CYP2C9 22/4885ALDH1A1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.